325 related articles for article (PubMed ID: 30489648)
1. Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.
Chen L; Hua J; Ross CA; Cai S; van Zijl PCM; Li X
J Neurosci Res; 2019 Apr; 97(4):467-479. PubMed ID: 30489648
[TBL] [Abstract][Full Text] [Related]
2. Elevated brain iron is independent from atrophy in Huntington's Disease.
Dumas EM; Versluis MJ; van den Bogaard SJ; van Osch MJ; Hart EP; van Roon-Mom WM; van Buchem MA; Webb AG; van der Grond J; Roos RA;
Neuroimage; 2012 Jul; 61(3):558-64. PubMed ID: 22480728
[TBL] [Abstract][Full Text] [Related]
3. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease.
van Bergen JM; Hua J; Unschuld PG; Lim IA; Jones CK; Margolis RL; Ross CA; van Zijl PC; Li X
AJNR Am J Neuroradiol; 2016 May; 37(5):789-96. PubMed ID: 26680466
[TBL] [Abstract][Full Text] [Related]
5. White and Gray Matter Abnormalities in Manifest Huntington's Disease: Cross-Sectional and Longitudinal Analysis.
Sweidan W; Bao F; Bozorgzad NS; George E
J Neuroimaging; 2020 May; 30(3):351-358. PubMed ID: 32128927
[TBL] [Abstract][Full Text] [Related]
6. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.
Tabrizi SJ; Scahill RI; Durr A; Roos RA; Leavitt BR; Jones R; Landwehrmeyer GB; Fox NC; Johnson H; Hicks SL; Kennard C; Craufurd D; Frost C; Langbehn DR; Reilmann R; Stout JC;
Lancet Neurol; 2011 Jan; 10(1):31-42. PubMed ID: 21130037
[TBL] [Abstract][Full Text] [Related]
7. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study.
Politis M; Pavese N; Tai YF; Kiferle L; Mason SL; Brooks DJ; Tabrizi SJ; Barker RA; Piccini P
Hum Brain Mapp; 2011 Feb; 32(2):258-70. PubMed ID: 21229614
[TBL] [Abstract][Full Text] [Related]
8. Regional subcortical shape analysis in premanifest Huntington's disease.
Tang X; Ross CA; Johnson H; Paulsen JS; Younes L; Albin RL; Ratnanather JT; Miller MI
Hum Brain Mapp; 2019 Apr; 40(5):1419-1433. PubMed ID: 30376191
[TBL] [Abstract][Full Text] [Related]
9. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
Tabrizi SJ; Langbehn DR; Leavitt BR; Roos RA; Durr A; Craufurd D; Kennard C; Hicks SL; Fox NC; Scahill RI; Borowsky B; Tobin AJ; Rosas HD; Johnson H; Reilmann R; Landwehrmeyer B; Stout JC;
Lancet Neurol; 2009 Sep; 8(9):791-801. PubMed ID: 19646924
[TBL] [Abstract][Full Text] [Related]
10. Differential Changes in Functional Connectivity of Striatum-Prefrontal and Striatum-Motor Circuits in Premanifest Huntington's Disease.
Kronenbuerger M; Hua J; Bang JYA; Ultz KE; Miao X; Zhang X; Pekar JJ; van Zijl PCM; Duan W; Margolis RL; Ross CA
Neurodegener Dis; 2019; 19(2):78-87. PubMed ID: 31412344
[TBL] [Abstract][Full Text] [Related]
11. Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease.
Wu D; Faria AV; Younes L; Mori S; Brown T; Johnson H; Paulsen JS; Ross CA; Miller MI;
Hum Brain Mapp; 2017 Oct; 38(10):5035-5050. PubMed ID: 28657159
[TBL] [Abstract][Full Text] [Related]
12. Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study.
Johnson EB; Parker CS; Scahill RI; Gregory S; Papoutsi M; Zeun P; Osborne-Crowley K; Lowe J; Nair A; Estevez-Fraga C; Fayer K; Rees G; Zhang H; Tabrizi SJ;
EBioMedicine; 2021 Mar; 65():103266. PubMed ID: 33706250
[TBL] [Abstract][Full Text] [Related]
13. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study.
Peinemann A; Schuller S; Pohl C; Jahn T; Weindl A; Kassubek J
J Neurol Sci; 2005 Dec; 239(1):11-9. PubMed ID: 16185716
[TBL] [Abstract][Full Text] [Related]
14. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis.
Scahill RI; Zeun P; Osborne-Crowley K; Johnson EB; Gregory S; Parker C; Lowe J; Nair A; O'Callaghan C; Langley C; Papoutsi M; McColgan P; Estevez-Fraga C; Fayer K; Wellington H; Rodrigues FB; Byrne LM; Heselgrave A; Hyare H; Sampaio C; Zetterberg H; Zhang H; Wild EJ; Rees G; Robbins TW; Sahakian BJ; Langbehn D; Tabrizi SJ
Lancet Neurol; 2020 Jun; 19(6):502-512. PubMed ID: 32470422
[TBL] [Abstract][Full Text] [Related]
15. Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease.
Orth M; Gregory S; Scahill RI; Mayer IS; Minkova L; Klöppel S; Seunarine KK; Boyd L; Borowsky B; Reilmann R; Bernhard Landwehrmeyer G; Leavitt BR; Roos RA; Durr A; Rees G; Rothwell JC; Langbehn D; Tabrizi SJ;
Hum Brain Mapp; 2016 Dec; 37(12):4615-4628. PubMed ID: 27477323
[TBL] [Abstract][Full Text] [Related]
16. Iron accumulation in the basal ganglia in Huntington's disease: cross-sectional data from the IMAGE-HD study.
Domínguez JF; Ng AC; Poudel G; Stout JC; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
J Neurol Neurosurg Psychiatry; 2016 May; 87(5):545-9. PubMed ID: 25952334
[TBL] [Abstract][Full Text] [Related]
17. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ
Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473
[TBL] [Abstract][Full Text] [Related]
18. Comparison of quantitative susceptibility mapping methods for iron-sensitive susceptibility imaging at 7T: An evaluation in healthy subjects and patients with Huntington's disease.
Yao J; Morrison MA; Jakary A; Avadiappan S; Chen Y; Luitjens J; Glueck J; Driscoll T; Geschwind MD; Nelson AB; Villanueva-Meyer JE; Hess CP; Lupo JM
Neuroimage; 2023 Jan; 265():119788. PubMed ID: 36476567
[TBL] [Abstract][Full Text] [Related]
19. Shape analysis of subcortical nuclei in Huntington's disease, global versus local atrophy--results from the TRACK-HD study.
van den Bogaard SJ; Dumas EM; Ferrarini L; Milles J; van Buchem MA; van der Grond J; Roos RA
J Neurol Sci; 2011 Aug; 307(1-2):60-8. PubMed ID: 21624624
[TBL] [Abstract][Full Text] [Related]
20. Early atrophy of pallidum and accumbens nucleus in Huntington's disease.
van den Bogaard SJ; Dumas EM; Acharya TP; Johnson H; Langbehn DR; Scahill RI; Tabrizi SJ; van Buchem MA; van der Grond J; Roos RA;
J Neurol; 2011 Mar; 258(3):412-20. PubMed ID: 20936300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
